ORIC Pharmaceuticals Selects Phase 3 Dose for Prostate Cancer Treatment

ORIC Pharmaceuticals has announced the selection of 400 mg once daily as the Recommended Phase 3 Dose (RP3D) for its drug Rinzimetostat. The drug will be utilized in combination with darolutamide for the upcoming Himalayas-1 global Phase 3 registrational trial. This study specifically targets patients with post-abiraterone metastatic castration-resistant prostate cancer (mCRPC). The clinical trial initiation is currently projected for the first half of 2026, following positive dose optimization data that supports its potential as a best-in-disease treatment. This selection marks a significant clinical milestone for the biotech company, signaling steady progress toward potential commercialization. Investors view this development as a positive step in ORIC's oncology pipeline, despite the trial start being scheduled for 2026.